For US Healthcare Professionals
|
|
|
Patients should read the product information before they start taking a product and each time they refill their prescription in case any information has changed. The product information provides only a summary for the patient. It does not take the place of discussion between patients and their doctors.
|
EMEND® (fosaprepitant dimeglumine) for Injection
|
|
JANUMET® (sitagliptin/metformin HCl) tablets
(Please read the Boxed Warning about lactic acidosis in the Prescribing Information.)
|
|
MAXALT® (rizatriptan benzoate) Tablets
|
|
MAXALT-MLT® (rizatriptan benzoate) Orally Disintegrating Tablets
|
|
NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring) delivers 0.120 mg/0.015 mg per day
(Please read the Boxed Warning about serious cardiovascular events, especially in women who smoke, in the Prescribing Information.)
|
|
|
|
|
TEMODAR® (temozolomide) for Injection
|
|
VYTORIN® (ezetimibe/simvastatin) Tablets
|
|
ZETIA® (ezetimibe) Tablets
|
|
|
|
This is not a complete list of Merck products. For a full listing of Merck products, please visit Prescribing Information for all Merck Products.
|
|
|
Ask a Product-Related Question or Report an Adverse Event
Let us assist you with information and services related to Merck and its products.
Get Started
The Merck National Service Center will be pleased to assist you Monday–Friday from 8:00 AM–7:00 PM ET. Adverse events and product-related emergencies will be handled at any time.
|
|
All product names listed on this site are registered trademarks owned by or licensed to a subsidiary of Merck & Co., Inc.
MerckProductServices, MerckServices, MerckSource, Merck OnCall, MerckMedicus, and MerckEngage are trademarks or registered trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
|
|
|
|
